Kathryn Zoon Biography and Net Worth

Director of Emergent Biosolutions

Dr. Zoon has served as a director since October 2016. Dr. Zoon is currently a Scientist Emeritus with the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH). Previously at NIAID/NIH she was the Chief of the Cytokine Biology Section, Director of the Division of Intramural Research (DIR), and Deputy Director for Planning and Development at the DIR. Dr. Zoon has also served as the Principal Deputy Director of the Center for Cancer Research at the National Cancer Institute, and as the Director of the Center for Biologics Evaluation and Research at the Food and Drug Administration. She has been a member of the National Academy of Medicine since 2002. Dr. Zoon received her B.S. degree from Rensselaer Polytechnic Institute and was granted a Ph.D. from the Johns Hopkins University.

What is Kathryn C. Zoon's net worth?: The estimated net worth of Kathryn C. Zoon is at least $864.68 thousand as of August 15th, 2025. Zoon owns 71,799 shares of Emergent Biosolutions stock worth more than $864,675 as of December 5th. This net worth approximation does not reflect any other assets that Zoon may own. Learn More about Kathryn C. Zoon's net worth.
How do I contact Kathryn C. Zoon?: The corporate mailing address for Zoon and other Emergent Biosolutions executives is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. Emergent Biosolutions can also be reached via phone at (240) 631-3200 and via email at [email protected]. Learn More on Kathryn C. Zoon's contact information.
Has Kathryn C. Zoon been buying or selling shares of Emergent Biosolutions?: Kathryn C. Zoon has not been actively trading shares of Emergent Biosolutions during the last quarter. Most recently, Kathryn C. Zoon sold 7,086 shares of the business's stock in a transaction on Friday, August 15th. The shares were sold at an average price of $8.87, for a transaction totalling $62,852.82. Following the completion of the sale, the director now directly owns 71,799 shares of the company's stock, valued at $636,857.13. Learn More on Kathryn C. Zoon's trading history.
Who are Emergent Biosolutions' active insiders?: Emergent Biosolutions' insider roster includes Neal Fowler (Director), Keith Katkin (Director), Richard Lindahl (CFO), and Kathryn Zoon (Director). Learn More on Emergent Biosolutions' active insiders.
Are insiders buying or selling shares of Emergent Biosolutions?: During the last twelve months, insiders at the biopharmaceutical company sold shares 5 times. They sold a total of 88,382 shares worth more than $690,250.62. The most recent insider tranaction occured on October, 7th when EVP Coleen Glessner sold 30,608 shares worth more than $306,080.00. Insiders at Emergent Biosolutions own 1.2% of the company. Learn More about insider trades at Emergent Biosolutions.
Information on this page was last updated on 10/7/2025.

Kathryn C. Zoon Insider Trading History at Emergent Biosolutions

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/15/2025	Sell	7,086	$8.87	$62,852.82	71,799
6/4/2024	Sell	10,000	$6.11	$61,100.00	54,482
5/29/2024	Sell	1,830	$4.61	$8,436.30	64,482
5/21/2024	Sell	1,089	$5.78	$6,294.42	48,882
6/2/2023	Sell	1,830	$8.35	$15,280.50	49,971
5/25/2023	Sell	1,700	$8.38	$14,246.00	51,801
6/9/2022	Sell	1,173	$31.52	$36,972.96	19,654
5/24/2022	Sell	1,996	$35.53	$70,917.88	12,381
5/25/2021	Sell	3,139	$56.48	$177,290.72	14,377
3/4/2020	Sell	991	$60.65	$60,104.15	16,421
11/18/2019	Sell	1,000	$54.06	$54,060.00
11/8/2019	Sell	3,082	$54.15	$166,890.30	18,412
9/9/2019	Sell	1,509	$56.12	$84,685.08	21,494
5/28/2019	Sell	1,376	$43.39	$59,704.64	24,379
11/7/2018	Sell	4,242	$69.74	$295,837.08	33,972
6/6/2018	Sell	376	$52.81	$19,856.56	22,885
5/24/2018	Sell	1,377	$51.15	$70,433.55

Kathryn C. Zoon Buying and Selling Activity at Emergent Biosolutions

Emergent Biosolutions Company Overview

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Today's Range

Now: $12.04

$11.52

$12.28

50 Day Range

MA: $10.09

$8.81

$12.78

2 Week Range

Now: $12.04

$4.02

$13.41

Volume

1,124,806 shs

Average Volume

827,770 shs

Market Capitalization

$632.50 million

P/E Ratio

9.26

Dividend Yield

N/A

Beta

2.32